TY - JOUR T1 - A Snapshot of COVID-19 Incidence, Hospitalizations, and Mortality from Indirect Survey Data in China in January 2023 JF - medRxiv DO - 10.1101/2023.02.22.23286167 SP - 2023.02.22.23286167 AU - Juan M. Ramírez AU - Sergio Díaz-Aranda AU - Jose Aguilar AU - Oluwasegun Ojo AU - Rosa Elvira Lillo AU - Antonio Fernández Anta Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/02/27/2023.02.22.23286167.abstract N2 - In this work we estimate the incidence of COVID-19 in China using online indirect surveys (which preserve the privacy of the participants). The indirect surveys deployed collect data on the incidence of COVID-19, asking the participants about the number of cases, deaths, vaccinated, and hospitalized that they know. The incidence of COVID-19 (cases, deaths, etc.) is then estimated using a modified Network Scale-up Method (NSUM). Survey responses (100, 200 and 1,000, respectively) were collected from Australia, the UK, and China in January 2023. The estimates in Australia and the UK are compared with official data, showing that they are in the confidence intervals or rather close. Cronbach’s alpha values also indicate good confidence in the estimates. The estimates obtained in China are, among others, that 91% of the population is vaccinated, almost 80% had been infected in the last month, and almost 3% in the last 24 hours.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially supported by grants COMODIN-CM and PredCov-CM, funded by Comunidad de Madrid and the European Union through the European Regional Development Fund (ERDF), and grants TED2021-131264B-I00 (SocialProbing) and PID2019-104901RB-I00, funded by Ministry of Science and Innovation - State Research Agency, Spain MCIN/AEI/10.13039/ 501100011033 and the European Union "NextGenerationEU"/PRTR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IMDEA Networks' IRB Research Ethics Panel, IMDEA Networks InstituteI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data collected in the indirect surveys is publicly available at https://github.com/GCGImdea/coronasurveys/tree/master/papers/2023-COVID-19-China-January. https://github.com/GCGImdea/coronasurveys/tree/master/papers/2023-COVID-19-China-January ER -